Business Wire

As the VMware vSphere 7 Support Deadline Nears, Spinnaker Announces Alternative Option to Keep VMware Customers Supported Indefinitely

22.9.2025 15:00:00 EEST | Business Wire | Press release

Share

Spinnaker Support (Spinnaker), the Oracle, SAP and VMware software support specialist trusted by over 1,000 global clients, including many of the world’s leading banks, telcos and utility companies, announces today that it will provide support for organizations running vSphere 7 indefinitely - meaning organizations running vSphere 7 for as long as they want past Broadcom’s End of General Support Deadline (EoGS) of October 2, 2025.

From October 2, 2025, Broadcom will no longer provide technical support, security patches, or updates for vSphere 7.x, and customers will need to upgrade to a newer version if they want to remain supported. If customers decide not to upgrade or simply don’t have the budget to do so, systems will become vulnerable.

“Broadcom is essentially telling customers “Upgrade now or you’ll be left behind”, and we believe that is wrong,” said Shane O'Rourke, Senior Director of VMware Global Support Services, Spinnaker Support. “This is why today we are announcing that VMware customers running vSphere 7 can continue to do so as long as they want and remain supported by our team of VMware experts. This once again demonstrates Broadcom’s attitude towards customers and ultimately forcing them to upgrade when they are happy with their current version.”

“Many of the customers I talk to are still running on version 7, often because it’s “just working” and nobody wants to fix what isn’t broken. But as support winds down, the risks for these customers only compound: no more CVEs, no more zero-day patches, and no guarantees if something fundamental fails. From my perspective, now is the time to step back and look at what’s actually right for your business, your use cases, and your environment, not just what the vendor lifecycle dictates,” added O’Rourke.

David McDougall, CRO, Spinnaker Support commented: “Since the Broadcom acquisition, ambiguity is the only thing we’ve been able to count on. Customers distrust the licensing changes, many outright reject the move to a subscription model, and most simply want to avoid getting caught in another round of sudden price hikes, changing terms, or forced upgrades driven by the vendor. VMware has unwittingly pushed many customers into running their environments unsupported. The decision to shed your support contract isn’t something anyone is doing without serious consideration, and many customers feel like they have no alternative in the face of the VMware changes. It’s critical that organizations know that there is an alternative support option available to them.”

For more information about Spinnaker Support’s VMware support offering, visit https://www.spinnakersupport.com/vmware/.

About Spinnaker Support

Spinnaker Support is entrusted by over 1,000 companies worldwide to solve their most pressing and essential enterprise software needs.

Spinnaker Support experts provide an extensive services portfolio of third-party support, managed services, consulting, and state-of-the-art security to optimize clients’ software ecosystems. They support Oracle, SAP, and VMware – freeing up valuable capital and resources so customers can maximize the security and performance of their enterprise software ecosystem with certainty. With Spinnaker, enterprises are empowered to make software decisions based on their business initiatives rather than their enterprise software provider’s roadmap.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250922678118/en/

Contacts

Media contact
Dan Walsh
dan@mustardpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye